Exposure to estrogen and ionizing radiation causes epigenetic dysregulation, activation of mitogen-activated protein kinase pathways, and genome instability in the mammary gland of ACI rats

Cancer Biology and Therapy

Volumn 14, Issue 7, 2013, Pages 564-573

  Kutanzi, Kristy ^a,b   Kovalchuk, Olga ^a  

^a UNIVERSITY OF LETHBRIDGE   (Canada)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Breast cancer; DNA methylation; Epigenetics; Estrogen; Histones; Ionizing radiation; Mitogen activated protein kinase pathways

Indexed keywords

BIOLOGICAL MARKER; DNA BINDING PROTEIN; DNA DIRECTED DNA POLYMERASE BETA; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; HISTONE H3; HISTONE H4; KU ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NIBRIN; PROTEIN APE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST HYPERPLASIA; CANCER MODEL; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; DNA END JOINING REPAIR; DNA METHYLATION; ENZYME ACTIVATION; EPIGENETICS; ESTROGEN ACTIVITY; EXCISION REPAIR; FEMALE; GENOMIC INSTABILITY; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE PHOSPHORYLATION; IONIZING RADIATION; MAMMARY GLAND; MORPHOLOGY; NONHUMAN; RADIATION CARCINOGENESIS; RADIATION EXPOSURE; RAT;

BREAST CANCER; DNA METHYLATION; EPIGENETICS; ESTROGEN; HISTONES; IONIZING RADIATION; MITOGEN-ACTIVATED PROTEIN KINASE PATHWAYS;

ANIMALS; CELL PROLIFERATION; DNA METHYLATION; EPIGENOMICS; ESTROGENS; FEMALE; GENOMIC INSTABILITY; IMMUNOHISTOCHEMISTRY; MAMMARY GLANDS, ANIMAL; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; RADIATION, IONIZING; RANDOM ALLOCATION; RATS; RATS, INBRED ACI; RATS, SPRAGUE-DAWLEY;

EID: 84881174513     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.24599     Document Type: Article

References (70)

1. Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 2004; 96: 1311-21; PMID:15339969; http://dx.doi.org/10.1093/jnci/ djh253
2. Jemal A, Siegel R, Ward E, Hao YP, Xu JQ, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96; PMID:18287387; http://dx.doi.org/10.3322/CA.2007.0010
3. Brody JG, Moysich KB, Humblet O, Attfield KR, Beehler GP, Rudel RA. Environmental pollutants and breast cancer: epidemiologic studies. Cancer 2007; 109(Suppl): 2667-711; PMID:17503436; http://dx.doi.org/10.1002/cncr.22655
4. Weyandt J, Ellsworth RE, Hooke JA, Shriver CD, Ellsworth DL. Environmental chemicals and breast cancer risk - a structural chemistry perspective. Curr Med Chem 2008; 15: 2680-701; PMID:18991630; http://dx.doi.org/10.2174/092986708786242930
5. Ronckers CM, Erdmann CA, Land CE. Radiation and breast cancer: a review of current evidence. Breast Cancer Res 2005; 7: 21-32; PMID:15642178; http://dx.doi.org/10.1186/bcr970
6. MacMahon B. Epidemiology and the causes of breast cancer. Int J Cancer 2006; 118: 2373-8; PMID:16358260; http://dx.doi.org/10.1002/ijc.21404
7. Boice JD Jr., Preston D, Davis FG, Monson RR. Frequent chest X-ray fluoroscopy and breast cancer incidence among tuberculosis patients in Massachusetts. Radiat Res 1991; 125: 214-22; PMID:1996380; http://dx.doi.org/10. 2307/3577890
8. Storm HH, Andersson M, Boice JD Jr., Blettner M, Stovall M, Mouridsen HT, et al. Adjuvant radiotherapy and risk of contralateral breast cancer. J Natl Cancer Inst 1992; 84: 1245-50; PMID:1640483; http://dx.doi.org/10.1093/jnci/84. 16.1245
9. Land CE, Tokunaga M, Koyama K, Soda M, Preston DL, Nishimori I, et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990. Radiat Res 2003; 160: 707-17; PMID:14640793; http://dx.doi.org/10.1667/RR3082
10. Mattsson A, Rudén BI, Hall P, Wilking N, Rutqvist LE. Radiation-induced breast cancer: long-term followup of radiation therapy for benign breast disease. J Natl Cancer Inst 1993; 85: 1679-85; PMID:8411245; http://dx.doi.org/10.1093/jnci/85.20.1679
11. Russo IH, Russo J. Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect 1996; 104: 938-67; PMID:8899375; http://dx.doi.org/10. 1289/ehp.96104938
12. Calaf GM, Hei TK. Establishment of a radiation- and estrogen-induced breast cancer model. Carcinogenesis 2000; 21: 769-76; PMID:10753214; http://dx.doi.org/10.1093/carcin/21.4.769
13. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354: 270-82; PMID:16421368; http://dx.doi.org/10.1056/NEJMra050776
14. Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 2006; 102: 89-96; PMID:17113977; http://dx.doi.org/10.1016/j.jsbmb.2006.09.004
15. Subramanian A, Salhab M, Mokbel K. Oestrogen producing enzymes and mammary carcinogenesis: a review. Breast Cancer Res Treat 2008; 111: 191-202; PMID:17934808; http://dx.doi.org/10.1007/s10549-007-9788-0
16. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability - an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11: 220-8; PMID:20177397; http://dx.doi.org/10.1038/nrm2858
17. Hinshelwood RA, Clark SJ. Breast cancer epigenetics: normal human mammary epithelial cells as a model system. J Mol Med (Berl) 2008; 86: 1315-28; PMID:18716754; http://dx.doi.org/10.1007/s00109-008-0386-3
18. Veeck J, Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia 2010; 15: 5-17; PMID:20101446; http://dx.doi.org/10.1007/s10911-010-9165-1
19. Dalvai M, Bystricky K. The role of histone modifications and variants in regulating gene expression in breast cancer. J Mammary Gland Biol Neoplasia 2010; 15: 19-33; PMID:20131086; http://dx.doi.org/10.1007/s10911-010-9167-z
20. Martens JWM, Margossian AL, Schmitt M, Foekens J, Harbeck N. DNA methylation as a biomarker in breast cancer. Future Oncol 2009; 5: 1245-56; PMID:19852739; http://dx.doi.org/10.2217/fon.09.89
21. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7: 21-33; PMID:16369569; http://dx.doi.org/10. 1038/nrg1748
22. Sawan C, Vaissière T, Murr R, Herceg Z. Epigenetic drivers and genetic passengers on the road to cancer. Mutat Res 2008; 642: 1-13; PMID:18471836; http://dx.doi.org/10.1016/j.mrfmmm.2008.03.002
23. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-92; PMID:17320506; http://dx.doi.org/10.1016/j.cell.2007.01.029
24. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene 2002; 21: 5462-82; PMID:12154408; http://dx.doi.org/10.1038/sj.onc. 1205606
25. Szyf M. Targeting DNA methylation in cancer. Ageing Res Rev 2003; 2: 299-328; PMID:12726777; http://dx.doi.org/10.1016/S1568-1637(03)00012-6
26. Weitzman SA, Turk PW, Milkowski DH, Kozlowski K. Free radical adducts induce alterations in DNA cytosine methylation. Proc Natl Acad Sci U S A 1994; 91: 1261-4; PMID:8108398; http://dx.doi.org/10.1073/pnas.91.4.1261
27. Valinluck V, Sowers LC. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res 2007; 67: 946-50; PMID:17283125; http://dx.doi.org/10.1158/0008-5472.CAN-06-3123
28. Prise KM, Pinto M, Newman HC, Michael BD. A review of studies of ionizing radiation-induced doublestrand break clustering. Radiat Res 2001; 156: 572-6; PMID:11604074; http://dx.doi.org/10.1667/0033-7587(2001)156[0572: AROSOI]2.0.CO;2
29. Bhat HK, Calaf G, Hei TK, Loya T, Vadgama JV. Critical role of oxidative stress in estrogen-induced carcinogenesis. Proc Natl Acad Sci U S A 2003; 100: 3913-8; PMID:12655060; http://dx.doi.org/10.1073/pnas.0437929100
30. Mobley JA, Brueggemeier RW. Estrogen receptormediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis 2004; 25: 3-9; PMID:14514655; http://dx.doi.org/10.1093/carcin/bgg175
31. Powell CL, Swenberg JA, Rusyn I. Expression of base excision DNA repair genes as a biomarker of oxidative DNA damage. Cancer Lett 2005; 229: 1-11; PMID:16157213; http://dx.doi.org/10.1016/j.canlet. 2004.12.002
32. Sargent RG, Brenneman MA, Wilson JH. Repair of site-specific double-strand breaks in a mammalian chromosome by homologous and illegitimate recombination. Mol Cell Biol 1997; 17: 267-77; PMID:8972207
33. Jackson SP. Sensing and repairing DNA doublestrand breaks. Carcinogenesis 2002; 23: 687-96; PMID:12016139; http://dx.doi.org/10.1093/carcin/23.5.687
34. Gu YS, Jin SF, Gao YJ, Weaver DT, Alt FW. Ku70- deficient embryonic stem cells have increased ionizing radiosensitivity, defective DNA end-binding activity, and inability to support V(D)J recombination. Proc Natl Acad Sci U S A 1997; 94: 8076-81; PMID:9223317; http://dx.doi.org/10.1073/pnas.94.15.8076
35. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009; 10: 295-304; PMID:19308066; http://dx.doi.org/10.1038/nrg2540
36. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074-80; PMID:11498575; http://dx.doi.org/10.1126/science.1063127
37. Moss TJ, Wallrath LL. Connections between epigenetic gene silencing and human disease. Mutat Res 2007; 618: 163-74; PMID:17306846; http://dx.doi.org/10. 1016/j.mrfmmm.2006.05.038
38. Okitsu CY, Hsieh CL. DNA methylation dictates histone H3K4 methylation. Mol Cell Biol 2007; 27: 2746-57; PMID:17242185; http://dx.doi.org/10.1128/MCB. 02291-06
39. Ooi SKT, Qiu C, Bernstein E, Li KQ, Jia D, Yang Z, et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 2007; 448: 714-7; PMID:17687327; http://dx.doi.org/10.1038/nature05987
40. Tryndyak VP, Kovalchuk O, Pogribny IP. Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer Biol Ther 2006; 5: 65-70; PMID:16322686; http://dx.doi.org/10.4161/cbt.5.1.2288
41. Barratt MJ, Hazzalin CA, Cano E, Mahadevan LC. Mitogen-stimulated phosphorylation of histone H3 is targeted to a small hyperacetylation-sensitive fraction. Proc Natl Acad Sci U S A 1994; 91: 4781-5; PMID:8197135; http://dx.doi.org/10.1073/pnas.91.11.4781
42. Chadee DN, Hendzel MJ, Tylipski CP, Allis CD, Bazett-Jones DP, Wright JA, et al. Increased Ser-10 phosphorylation of histone H3 in mitogen-stimulated and oncogene-transformed mouse fibroblasts. J Biol Chem 1999; 274: 24914-20; PMID:10455166; http://dx.doi.org/10.1074/jbc.274.35.24914
43. Dyson MH, Thomson S, Inagaki M, Goto H, Arthur SJ, Nightingale K, et al. MAP kinase-mediated phosphorylation of distinct pools of histone H3 at S10 or S28 via mitogen- and stress-activated kinase 1/2. J Cell Sci 2005; 118: 2247-59; PMID:15870105; http://dx.doi.org/10.1242/jcs.02373
44. Harvell DM, Strecker TE, Tochacek M, Xie B, Pennington KL, McComb RD, et al. Rat strainspecific actions of 17beta-estradiol in the mammary gland: correlation between estrogen-induced lobuloalveolar hyperplasia and susceptibility to estrogeninduced mammary cancers. Proc Natl Acad Sci U S A 2000; 97: 2779-84; PMID:10688907; http://dx.doi.org/10.1073/pnas.050569097
45. Ruhlen RL, Willbrand DM, Besch-Williford CL, Ma LX, Shull JD, Sauter ER. Tamoxifen induces regression of estradiol-induced mammary cancer in the ACI.COP-Ept2 rat model. Breast Cancer Res Treat 2009; 117: 517-24; PMID:18830694; http://dx.doi.org/10.1007/s10549-008-0169-0
46. Li JJ, Papa D, Davis MF, Weroha SJ, Aldaz CM, El-Bayoumy K, et al. Ploidy differences between hormone- and chemical carcinogen-induced rat mammary neoplasms: comparison to invasive human ductal breast cancer. Mol Carcinog 2002; 33: 56-65; PMID:11807958; http://dx.doi.org/10.1002/mc.10022
47. Shull JD, Spady TJ, Snyder MC, Johansson SL, Pennington KL. Ovary-intact, but not ovariectomized female ACI rats treated with 17beta-estradiol rapidly develop mammary carcinoma. Carcinogenesis 1997; 18: 1595-601; PMID:9276635; http://dx.doi.org/10.1093/carcin/18.8.1595
48. Tomatis L. The predictive value of rodent carcinogenicity tests in the evaluation of human risks. Annu Rev Pharmacol Toxicol 1979; 19: 511-30; PMID:378109; http://dx.doi.org/10.1146/annurev. pa.19.040179.002455
49. Schaffer BS, Lachel CM, Pennington KL, Murrin CR, Strecker TE, Tochacek M, et al. Genetic bases of estrogen-induced tumorigenesis in the rat: mapping of loci controlling susceptibility to mammary cancer in a Brown Norway x ACI intercross. Cancer Res 2006; 66: 7793-800; PMID:16885383; http://dx.doi.org/10. 1158/0008-5472.CAN-06-0143
50. Gould KA, Tochacek M, Schaffer BS, Reindl TM, Murrin CR, Lachel CM, et al. Genetic determination of susceptibility to estrogen-induced mammary cancer in the ACI rat: mapping of Emca1 and Emca2 to chromosomes 5 and 18. Genetics 2004; 168: 2113-25; PMID:15611180; http://dx.doi.org/10.1534/genetics. 104.033878
51. Shull JD. The rat oncogenome: comparative genetics and genomics of rat models of mammary carcinogenesis. Breast Dis 2007; 28: 69-86; PMID:18057545.
52. Starlard-Davenport A, Tryndyak VP, James SR, Karpf AR, Latendresse JR, Beland FA, et al. Mechanisms of epigenetic silencing of the Rassf1a gene during estrogen-induced breast carcinogenesis in ACI rats. Carcinogenesis 2010; 31: 376-81; PMID:20008439; http://dx.doi.org/10.1093/carcin/bgp304
53. Turk PW, Laayoun A, Smith SS, Weitzman SA. DNA adduct 8-hydroxyl-2'-deoxyguanosine (8-hydroxyguanine) affects function of human DNA methyltransferase. Carcinogenesis 1995; 16: 1253-5; PMID:7767994; http://dx.doi.org/10.1093/carcin/16.5.1253
54. Smith SS. Stalling of DNA methyltransferase in chromosome stability and chromosome remodelling (Review). [Review]. Int J Mol Med 1998; 1: 147-56; PMID:9852213.
55. Roll JD, Rivenbark AG, Jones WD, Coleman WB. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol Cancer 2008; 7: 7; PMID:18208603; http://dx.doi.org/10.1186/1476-4598-7-15
56. Agoston AT, Argani P, Yegnasubramanian S, De Marzo AM, Ansari-Lari MA, Hicks JL, et al. Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem 2005; 280: 18302-10; PMID:15755728; http://dx.doi.org/10.1074/jbc. M501675200
57. Johansen KM, Johansen J. Regulation of chromatin structure by histone H3S10 phosphorylation. Chromosome Res 2006; 14: 393-404; PMID:16821135; http://dx.doi.org/10.1007/s10577-006-1063-4
58. Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR, et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997; 106: 348-60; PMID:9362543; http://dx.doi.org/10.1007/s004120050256
59. Fischle W. Talk is cheap - cross-talk in establishment, maintenance, and readout of chromatin modifications. Genes Dev 2008; 22: 3375-82; PMID:19141469; http://dx.doi.org/10.1101/gad.1759708
60. Ota T, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 2002; 62: 5168-77; PMID:12234980.
61. Choi HS, Choi BY, Cho YY, Mizuno H, Kang BS, Bode AM, et al. Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation. Cancer Res 2005; 65: 5818-27; PMID:15994958; http://dx.doi.org/10.1158/0008-5472.CAN-05-0197
62. Li JJ, Weroha SJ, Lingle WL, Papa D, Salisbury JL, Li SA. Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proc Natl Acad Sci U S A 2004; 101: 18123-8; PMID:15601761; http://dx.doi.org/10.1073/pnas.0408273101
63. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 1997; 99: 1478-83; PMID:9119990; http://dx.doi.org/10.1172/JCI119309
64. Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, et al. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 2006; 207: 420-7; PMID:16419029; http://dx.doi.org/10.1002/jcp.20588
65. Torii S, Yamamoto T, Tsuchiya Y, Nishida E. ERK MAP kinase in G cell cycle progression and cancer. Cancer Sci 2006; 97: 697-702; PMID:16800820; http://dx.doi.org/10.1111/j.1349-7006.2006.00244.x
66. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, et al. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 2002; 16: 116-27; PMID:11773443; http://dx.doi.org/10.1210/me.16.1.116
67. Liao Y, Hung MC. Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis. Mol Cell Biol 2003; 23: 6836-48; PMID:12972603; http://dx.doi.org/10.1128/MCB.23.19.6836-6848.2003
68. Chou CH, Chen SU, Cheng JC. Radiation-induced interleukin-6 expression through MAPK/p38/NF-kappaB signaling pathway and the resultant antiapoptotic effect on endothelial cells through Mcl-1 expression with sIL6-Ralpha. Int J Radiat Oncol Biol Phys 2009; 75: 1553-61; PMID:19931737; http://dx.doi.org/10. 1016/j.ijrobp.2009.08.034
69. Ellsworth DL, Ellsworth RE, Liebman MN, Hooke JA, Shriver CD. Genomic instability in histologically normal breast tissues: implications for carcinogenesis. Lancet Oncol 2004; 5: 753-8; PMID:15581548; http://dx.doi.org/ 10.1016/S1470-2045(04)01653-5
70. Pogribny I, Yi P, James SJ. A sensitive new method for rapid detection of abnormal methylation patterns in global DNA and within CpG islands. Biochem Biophys Res Commun 1999; 262: 624-8; PMID:10471374; http://dx.doi.org/10.1006/ bbrc.1999.1187